Singapore: Japan Vaccine, a joint venture created by equal investments from Daiichi Sankyo and GlaxoSmithKline, started its operation from July 3, 2012.

Japan Vaccine will hold all development and marketing rights for prophylactic vaccines owned by both its parent companies and perform clinical development, marketing and sales activities in Japan. At the start of operations, Japan Vaccine will only handle the parent companies' existing vaccines. However, it will soon add to its portfolio other vaccine candidates currently in development and expected to be approved.

Japan Vaccine aims to utilize the strengths of both of its parent companies to protect a wide range of Japanese patients from infectious diseases as a highly specialized vaccine business. The organization of 220 employees is managed by Chairman & Co-CEO Toshihiro Ishikiriyama and President & Co-CEO Akira Nagano.

Some of the main products of the company are Cervarix (cervical cancer), Rotarix (rotavirus), seasonal flu vaccine, mumps vaccine, DTP vaccine and MR vaccine.